RxDoctor Payments Data

Angela Kemp

Family · Dallas, TXNPI 1942632427

Payments from drug & device makers

$4,710in general payments, 2019–2025

Across 253 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$634
  • Abbott$486
  • AbbVie$476
  • Novo Nordisk$458
  • AstraZeneca$390
  • GSK$323
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,58097%
  • Education$1303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,710 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$89,937
MounjaroTirzepatide47$55,482
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$35,895
RybelsusSemaglutide18$32,649
FarxigaDapagliflozin Propanediol36$31,525
JardianceEmpagliflozin22$25,099
EliquisApixaban27$23,064
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,809
MyrbetriqMirabegron26$22,288
Tresiba Flextouch U-200Insulin Degludec14$20,634
TrulicityDulaglutide18$18,778
EntrestoSacubitril/Valsartan15$15,316
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$15,113
Potassium Chloride53$12,764
JanuviaSitagliptin Phosphate13$10,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$458$122,58687 claims
Lilly USA, LLCMounjaro, Trulicity$95$74,26165 claims
AstraZenecaBreztri Aerosphere, Farxiga$390$67,42079 claims
GSKTrelegy Ellipta, Breo Ellipta$323$30,11441 claims
Boehringer IngelheimJardiance$137$25,09922 claims
PfizerEliquis$119$23,06427 claims
Astellas Pharma US IncMyrbetriq$113$22,28826 claims
NovartisEntresto$19$15,31615 claims
MerckJanuvia$91$10,81213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →